Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Tryptamine Therapeutics ( (AU:ENP) ).
Entropy Neurodynamics Limited has reported a change in the holdings of director Herwig Janssen, reflecting additional equity-based compensation in the form of fully paid ordinary shares. The company disclosed that Janssen received 1,931,012 new ordinary shares, valued at $64,109.59, issued in lieu of cash director fees for services provided between 12 May 2025 and 31 December 2025, following prior shareholder approval at the November 2025 AGM, underscoring the firm’s continued use of equity remuneration to conserve cash and further align board incentives with shareholder interests.
The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.
More about Tryptamine Therapeutics
Average Trading Volume: 2,158,840
Technical Sentiment Signal: Sell
Current Market Cap: A$51.5M
Learn more about ENP stock on TipRanks’ Stock Analysis page.